Patents by Inventor Kathryn Prickett
Kathryn Prickett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8759291Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: April 5, 2011Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Andrew A. Young, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20110195904Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: April 5, 2011Publication date: August 11, 2011Applicant: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. YOUNG, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20090054341Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: October 7, 2008Publication date: February 26, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. Young, Will Vine, Nigel R.A. Beeley, Kathryn Prickett
-
Patent number: 7442680Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: September 5, 2003Date of Patent: October 28, 2008Assignee: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. Young, Will Vine, Nigel R. A. Beeley, Kathryn Prickett
-
Publication number: 20070066528Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.Type: ApplicationFiled: September 8, 2006Publication date: March 22, 2007Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Beeley, Kathryn Prickett, Andrew Young, David Hathaway
-
Publication number: 20070010656Abstract: Novel exendin agonist compounds are provided.Type: ApplicationFiled: August 28, 2006Publication date: January 11, 2007Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Beeley, Kathryn Prickett
-
Publication number: 20060148713Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: March 3, 2006Publication date: July 6, 2006Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Beeley, Kathryn Prickett, Sunil Bhavsar, Andrew Young
-
Publication number: 20060135747Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: ApplicationFiled: December 12, 2005Publication date: June 22, 2006Inventors: Odile Levy, Carolyn Jodka, Soumitra Ghosh, David Parkes, Richard Pittner, Lawrence D'Souza, John Ahn, Kathryn Prickett, Jonathan Roth, Sean Adams
-
Publication number: 20060094653Abstract: The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif.Type: ApplicationFiled: February 11, 2005Publication date: May 4, 2006Inventors: Odile Levy, Carolyn Jodka, Soumitra Ghosh, David Parkes, Richard Pittner, Lawrence D'Souza, John Ahn, Kathryn Prickett
-
Publication number: 20060074012Abstract: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.Type: ApplicationFiled: November 17, 2005Publication date: April 6, 2006Applicant: Amylin Pharmaceuticals, Inc.Inventors: Richard Hiles, Kathryn Prickett
-
Publication number: 20050267034Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: ApplicationFiled: June 30, 2005Publication date: December 1, 2005Inventors: Kathryn Prickett, Andrew Young
-
Publication number: 20050215469Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: July 19, 2004Publication date: September 29, 2005Inventors: Nigel Beeley, Kathryn Prickett, Sunil Bhavsar, Andrew Young, Bronislava Gedulin
-
Patent number: 6936584Abstract: Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.Type: GrantFiled: February 5, 1999Date of Patent: August 30, 2005Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel R. A. Beeley, Kathryn Prickett, Kevin Beaumont
-
Publication number: 20050101537Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: October 14, 2004Publication date: May 12, 2005Inventors: Nigel Robert Beeley, Kathryn Prickett, Sunil Bhavsar, Andrew Young
-
Publication number: 20050059601Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: October 15, 2004Publication date: March 17, 2005Inventors: Nigel Beeley, Kathryn Prickett, Sunil Bhavsar
-
Publication number: 20050037958Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: September 5, 2003Publication date: February 17, 2005Inventors: Andrew Young, Will Vine, Nigel Beeley, Kathryn Prickett
-
Patent number: 6703359Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: September 22, 2000Date of Patent: March 9, 2004Assignee: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. Young, Will Vine, Nigel R. A. Beeley, Kathryn Prickett
-
Patent number: 5625032Abstract: Peptides that inhibit amylin activity and that exhibit selectivity for amylin receptors relative to calcitonin and CGRP receptors are provided. These peptides may be used in the treatment of conditions where it is of benefit to reduce amylin activity, including the treatment of Type 2 diabetes mellitus, impaired glucose tolerance, obesity, insulin resistance and hypertension.Type: GrantFiled: July 21, 1993Date of Patent: April 29, 1997Assignee: Amylin Pharmaceuticals, Inc.Inventors: Lori Gaeta, Kevin Beaumont, Kathryn Prickett